225 results on '"Master V"'
Search Results
2. NODESAFE nomogram: A novel score system to predict lymph node involvement at the time of nephrectomy or nodal recurrence in non-metastatic renal cell carcinoma
3. Decoding benign renal cortical lesions: A machine learning approach from the INMARC registry
4. Impact of positive surgical margin after radical and partial nephrectomy for renal cell carcinoma: A multicenter analysis
5. Comparative analysis of oncological and functional outcomes of radical and partial nephrectomy in pT3aN0M0 renal cell carcinoma: A multicenter propensity score-matched analysis
6. Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial
7. Characteristics, Treatment and Outcomes of Patients with Primary Urethral Cancer: A Multi-Center Review over Two Decades
8. RTOG/NRG 1115 Quality of Life of Phase III Dose Escalated Radiation Therapy (RT) and Standard Androgen Deprivation Therapy (ADT) with GnRH Agonist vs. Dose Escalated RT and ADT with GnRH Agonist and Orteronel (TAK-700) for Men with High-Risk Prostate
9. Phase III Trial of Dose Escalated Radiation Therapy and Standard Androgen Deprivation Therapy (ADT) vs. Dose Escalated Radiation Therapy and Enhanced ADT with TAK-700 for Men with High-Risk Prostate Cancer (NRG Oncology/RTOG 1115)
10. Scrotal Emergencies
11. Comparable outcomes following two or three cycles of high-dose chemotherapy and autologous stem cell transplantation for patients with relapsed/refractory germ cell tumors
12. A randomized, double-blind, placebo-controlled, phase 3 trial of infigratinib as adjuvant therapy in patients with invasive urothelial carcinoma harboring susceptible FGFR3 genetic alterations: PROOF 302
13. TEP/TDM au 89ZR-DFO-Girentuximab pour l’imagerie des carcinomes rénaux à cellules claires–résultats de l’étude de phase III ZIRCON
14. Permanent His Bundle Pacing in Patients With Congenital Complete Heart Block: A Multicenter Experience
15. Patient perspective on serving on the steering committee of the AURORAX-0087A trial for non-metastatic clear cell renal cell carcinoma
16. Impact of post-operative proteinuria on development of CKD: Analysis of functional outcomes post nephrectomy
17. Grade migration in prostate cancer: an analysis using the Surveillance, Epidemiology, and End Results registry
18. ‘Insignificant’ prostate cancer on biopsy: pathologic results from subsequent radical prostatectomy
19. Lack of survival benefit of post-operative radiation therapy in prostate cancer patients with positive lymph nodes
20. Initial Report of a Randomized Trial Comparing Conventional- vs Conventional plus Fluciclovine (18F) PET/CT Imaging-Guided Post-Prostatectomy Radiotherapy for Prostate Cancer
21. Glycosaminoglycan (GAG) scores for surveillance of recurrence in Leibovich Points ≥5 non-metastatic clear cell renal cell carcinoma: AURORAX-0087A trial in progress report
22. Prostate cancer treatment ascertained from several sources: analysis of disagreement and error
23. Intratumor C-Reactive Protein as a Biomarker of Prognosis in Localized Renal Cell Carcinoma
24. Impact of diabetes mellitus on functional and survival outcomes in renal cell carcinoma: An international multicenter study
25. Multicenter comparison of outcomes for clinical and pathologic T3a renal cell carcinoma
26. Impact of change in post surgical serum C-reactive protein on outcomes in renal cell carcrinoma
27. Re: Absolute Preoperative C-Reactive Protein Predicts Metastasis and Mortality in the First Year Following Potentially Curative Nephrectomy for Clear Cell Renal Cell Carcinoma
28. Absolute Preoperative C-Reactive Protein Predicts Metastasis and Mortality in the First Year Following Potentially Curative Nephrectomy for Clear Cell Renal Cell Carcinoma
29. Repeated dose inhaled budesonide versus placebo in the treatment of croup
30. Elevated C-reactive protein is associated with functional decline following surgery for renal cell carcinoma: Results of an international cohort study
31. Negative impact of positive margins in partial nephrectomy in stage 1 renal cell carcinoma: A multicenter analysis
32. Proposal for tripartite reclassification of cT1 renal cell carcinoma into cT1a (very low risk), cT1b (low risk), and cT1c (intermediate risk) substages
33. Impact of sex on prognosis of non-metastatic clear cell renal cell carcinoma patients undergoing curative surgery: An inverse probability of treatment weighting analysis
34. Development and validation of a novel scoring index CART (C-reactive protein, age, race, tumor size) to predict renal functional decline post partial nephrectomy
35. Sites of metastasis and association with clinical outcome (CO) in advanced stage cancer patients (pts) treated with immunotherapy (IO)
36. Axitinib vs placebo in patients at high risk of recurrent renal cell carcinoma (RCC): ATLAS trial results
37. P124 - A randomized, double-blind, placebo-controlled, phase 3 trial of infigratinib as adjuvant therapy in patients with invasive urothelial carcinoma harboring susceptible FGFR3 genetic alterations: PROOF 302
38. 642 - External validation of the Mayo Clinic Stage, Size, Grade, and Necrosis score in patients with renal cell carcinoma and venous tumor thrombus
39. Renal cell carcinoma with inferior vena cava involvement: Prognostic effect of tumor thrombus consistency on cancer specific survival
40. Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy
41. P081 - Glycosaminoglycan (GAG) scores for surveillance of recurrence in Leibovich Points ≥5 non-metastatic clear cell renal cell carcinoma: AURORAX-0087A trial in progress report
42. Interim analysis of the phase 3 ADAPT trial evaluating rocapuldencel-T (AGS-003), an individualized immunotherapy for the treatment of newly-diagnosed patients with metastatic renal cell carcinoma (mRCC)
43. External validation of the Mayo Clinic Stage, Size, Grade, and Necrosis score in patients with renal cell carcinoma and venous tumor thrombus
44. 1049 - Development and validation of a novel scoring index CART (C-reactive protein, age, race, tumor size) to predict renal functional decline post partial nephrectomy
45. 1047 - Elevated C-reactive protein is associated with functional decline following surgery for renal cell carcinoma: Results of an international cohort study
46. 871 - Impact of sex on prognosis of non-metastatic clear cell renal cell carcinoma patients undergoing curative surgery: An inverse probability of treatment weighting analysis
47. 332 - Negative impact of positive margins in partial nephrectomy in stage 1 renal cell carcinoma: A multicenter analysis
48. S262 Detection of Von-Hippel Lindau methylation in renal cell carcinoma: Specificity and sensitivity of MALDI-TOF mass spectroscopy
49. 1221P - Sites of metastasis and association with clinical outcome (CO) in advanced stage cancer patients (pts) treated with immunotherapy (IO)
50. 863O - Axitinib vs placebo in patients at high risk of recurrent renal cell carcinoma (RCC): ATLAS trial results
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.